Author

R. Roskoski

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Final efficacy and safety data from the Phase I/II ARROW study of pralsetinib in patients with advanced REarranged during Transfection fusion-positive non-small cell lung cancer

. Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer

R. Roskoski · Journal of Thoracic Disease · 0 citations

Review Open access Oct 2026

Blockade of mutant RAS oncogenic signaling: a 2026 update.

Daraxonrasib, which is an indirect inhibitor of wildtype and mutant H/K/NRAS isoforms, is FDA approved for the second-line treatment of all RAS-mutant pancreatic cancers.

R. Roskoski · Pharmacological Research · 0 citations